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Abstract
Background: The “treatment gap” (TG) for mental disorders, widely advocated by the WHO in low-and middle-
income countries, is an important indicator of the extent to which a health system fails to meet the care needs of
people with mental disorder at the population level. While there is limited research on the TG in these countries,
there is even a greater paucity of studies looking at TG beyond a unidimensional understanding. This study
explores several dimensions of the TG construct for people with psychosis in Sodo, a rural district in Ethiopia, and
its implications for building a more holistic capacity for mental health services.
Method: The study was a cross-sectional survey of 300 adult participants with psychosis identified through
community-based case detection and confirmed through subsequent structured clinical evaluations. The Butajira
Treatment Gap Questionnaire (TGQ), a new customised tool with 83 items developed by the Ethiopia research
team, was administered to evaluate several TG dimensions (access, adequacy and effectiveness of treatment, and
impact/consequence of the treatment gap) across a range of provider types corresponding with the WHO pyramid
service framework.
Results: Lifetime and current access gap for biomedical care were 41.8 and 59.9% respectively while the
corresponding figures for faith and traditional healing (FTH) were 15.1 and 45.2%. Of those who had received
biomedical care for their current episode, 71.7% did not receive minimally adequate care. Support from the
community and non-governmental organisations (NGOs) were negligible. Those with education (Adj. OR: 2.1; 95%
CI: 1.2, 3.8) and history of use of FTH (Adj. OR: 3.2; 95% CI: 1.9–5.4) were more likely to use biomedical care.
Inadequate biomedical care was associated with increased lifetime risk of adverse experiences, such as history of
restraint, homelessness, accidents and assaults.
Conclusion: This is the first study of its kind. Viewing TG not as a unidimensional, but as a complex, multi-
dimensional construct, offers a more realistic and holistic understanding of health beliefs, help-seeking behaviors,
and need for care. The reconceptualized multidimensional TG construct could assist mental health services capacity
building advocacy and policy efforts and allow community and NGOs play a larger role in supporting mental
healthcare.
Keywords: Treatment gap, The Butajira treatment gap questionnaire, Treatment coverage, Treatment access, Severe
mental disorder, Low and middle-income country, Developing country
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Background
The treatment gap is an important concept in global
health advocacy with applicability across a range of
chronic medical conditions such as HIV/AIDS [1],
hypertension [2], cardiovascular diseases [3], diabetes
[3], epilepsy [4] and mental disorders [5]. For all condi-
tions, the treatment gap is defined as the proportion of
people with disorder who require an intervention but do
not receive one. The treatment gap for mental disorders
is universally large, although particularly marked in low
and middle-income countries (LMIC) [5, 6], with almost
four out of five persons with severe mental disorders in
LMIC receiving no treatment in the previous year [7, 8].
This is even larger in sub-Saharan Africa with nine in
ten people with schizophrenia not receiving care [9, 10].
In Ethiopia, the Butajira study on the course and out-
come of severe mental illnesses 15 years ago, reported a
lifetime treatment access gap for schizophrenia and bi-
polar disorder of 90% [11, 12], with similar national rates
more recently [9].
The treatment gap is an indicator of the extent to
which a health system fails to meet the care needs of
people with a specific disorder at the population level.
As such, changes in the treatment gap is an import-
ant metric for tracking progress in improving treat-
ment coverage in moving towards universal health
care [13]. However, current measures of the treatment
gap, consisting of direct and indirect approaches, are
conceptually inadequate and are criticised for ignoring
the broader range of services or ‘plurality’ of care
[14]. The potential negative consequences of not re-
ceiving care, particularly relevant in places with high
‘treatment gap’, where potential for human rights vio-
lations may be substantial [15], are also overlooked.
Thus, broadening the definition and applicability of
the treatment gap to varied contexts, interventions
and outcomes is pertinent. In this paper we re-
conceptualise the treatment gap as a multi-
dimensional construct and evaluate its burden in
people with psychosis at the point of engagement
with a new integrated service in rural Ethiopia.
Re-conceptualising the treatment gap
Our re-conceptualisation is based on two premises.
First, as indicated above, is the need to consider the
plurality of care and the power of individuals to use
the care they choose. The service pyramid of the
WHO [16] is a useful framework for defining and
measuring this plurality of care. In addition to bio-
medical care, it is contextually appropriate to quantify
access to FTH providers as well as support from the
community, non-governmental organisations, family
and self-care. The second premise is the need to
move away from treatment for a disorder to the goal
of treatment, “recovery” and “recovery” gap with em-
phasis on what is meaningful to the person in need.
In this regard, the treatment gap is viewed as a con-
tinuum, with the continuum moving from lack of ac-
cess to any evidence-based care during the whole
duration of the illness (lifetime access gap) to failure
to achieve the goal of treatment, recovery (recovery
gap) (Table 1 and Fig. 1). The most severe form of
access gap is the lifetime access gap, which provides
information about the severity of population level
neglect, and may have particular relevance in LMIC
settings.
The quality and adequacy gaps are directly relevant to
effectiveness and recovery gaps. Although ‘quality’ has
several meanings in health service research, the quality
gap here represents how different the care provided is to
accepted quality standards or treatment guidelines and
to implicit requirements such as patient satisfaction [18].
The adequacy gap relates to the adequacy of treatment
in terms of dose/intensity, continuity and duration. A
simple method of measuring the adequacy gap may be
assessing the frequency of service encounters in combin-
ation with the appropriateness of the prescribed treat-
ment [19]. Ultimately, the goal of treatment is to achieve
full recovery [20]; thus, the target goal for policy initia-
tives and care provision has to be to reduce the recovery
gap. The recovery gap is an important indicator of the
inadequacies of the implementation of current evidence-
based care. For example, a large proportion of patients
receiving treatment for severe [21] or less severe ill-
nesses [22] fail to achieve recovery.
There are two additional dimensions, which are of
major importance: equity and impact or consequence.
Equity is a cross-cutting dimension and a reflection of
whether the lack of treatment or the benefits of treat-
ment are distributed across the whole population in
need without discrimination. The final dimension of the
treatment gap evaluates the consequence or impact of
the treatment gap on the affected individual, family and
the wider community. Estimating the consequences of
the treatment gap will show why the treatment gap mat-
ters. In addition to the direct illness burden, one of the
key consequences of the treatment gap is human rights
abuse from various sources including through the
process of receiving care.
Redefining the treatment gap in this more nuanced
multi-dimensional way extends applicability to ore set-
tings and allows for a more refined analysis and identifi-
cation of targeted policy interventions.
The aim of this study was to determine the various di-
mensions of the treatment gap for psychosis in a setting
where a new service programme, the Programme for Im-
proving Mental Healthcare (PRIME) [23], was being
implemented.
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Methods
The study was a cross-sectional assessment of adults
with confirmed diagnosis of psychosis. The study par-
ticipants were identified through community case de-
tection and subsequent structured clinical evaluation
of diagnosis.
Setting
The study was conducted in the Sodo district, Gurage
Zone, Southern Nations, Nationalities and Peoples’ Re-
gion (SNNPR) of Ethiopia. We have reported previously
on the study setting [24, 25]. Sodo is a predominantly
rural district located about 100 km south of the capital
city, Addis Ababa. The district hosts one primary
hospital, eight health centres and 58 health posts (com-
munity based health facilities).
Case identification
We used a two-stage case identification process for
recruiting participants (Fig. 2).
First, potential cases with psychosis were identified
and referred by community key informants [26], consist-
ing of health extension workers and community leaders
trained for half a day by a psychiatrist with experience in
training key informants. Health extension workers are
healthcare staff with one year of training in healthcare
after completing high school education. They staff the
health posts located within the communities and also
reside within the communities they serve. These health
Table 1 Definitions of the treatment gap dimensions and how they may be measured
Care/
treatment
gap
dimensions
Definition How measured
Subjective Objective
Access
• Lifetime Whether there ‘ever’ was access to
evidence-based care since onset of
illness without any judgment about
efficacy
Self-reported access over the course of
illness since onset
Linkage based on databases (electronic
or other records)
• Current Whether there was access to
evidence-based care for the current
or most recent episode of illness
Self-reported access during the current
or most recent episode of illness
Linkage based on databases (electronic
or other records)
Adequacy Whether adequate quantity of
treatment was provided in terms
of the nature, dose and duration
of treatment
Self-reported minimum adequacy standard Recorded information compared with
established standard of care
Quality Attainment of a certain standard
and meeting certain intrinsic
characteristics of care such as
patient satisfaction and concordance
with patient values
Self-reported patient satisfaction Evaluation of whether care is concordant
with established quality standards
and guidelines
Effectiveness Intended outcomes of clinical
improvement achieved with little
untoward consequences and
inconvenience to user
Self-reported benefit of care Standard scales of effectiveness
Recovery This is the ultimate goal of treatment
and understood in three ways:
• Sustained clinical wellness
(well for at least 6 months)
• Functional wellness (regaining
full functionality)
• As a process of change that
allows individuals to “improve their
health and wellness, live a self-directed
life, and strive to reach their full
potential” [17]
Self-reported recovery Standard scales of recovery may be used
Equity Is relevant to all dimensions of care
or treatment gap and equitable care
ensures that access, quality or impact
of care “does not vary in quality
because of personal characteristics
such as gender, race, ethnicity,
geographical location, or
socioeconomic status.”
Analysis of variation of care and treatment
gap by the various equity dimensions.
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workers visit households about once a month and have
intimate knowledge of their communities. Second, these
potential cases were referred to the health centres where
trained psychiatric nurses conducted a semi-structured
interview to confirm diagnosis and evaluate other clin-
ical parameters, such as symptom severity. To be in-
cluded in the study, participants had to be at least 18
years of age, fulfil diagnostic criteria of the International
Classification of Diseases (ICD) [27] for one of the major
psychotic disorders ((ICD-10 F20 and ICD-10 F30
[psychotic subsections]), be in need of mental health
care at the time of detection, and were resident in the
area for at least six months. The study was conducted
between December 2014 and August 2015.
Assessment of diagnosis and other clinical and social
parameters
The Operational Criteria for Research (OPCRIT) [28], a
semi-structured checklist for genetic studies, was used to
support clinical diagnosis. The instrument uses some of
the rating styles of the Schedules for Clinical Assessment
in Neuropsychiatry (SCAN) [29] but is briefer and sim-
pler to administer. It has established reliability and al-
lows application of multiple diagnostic criteria [28].
Measurement of the treatment gap
The Butajira Treatment Gap Questionnaire (TGQ) was
used to establish the treatment gap (available at http://
bit.ly/2oPlqmQ). The TGQ is an 83 items questionnaire
Fig. 2 Flow diagram of patient recruitment (*Assuming 54% of the total population to be adults)
Fig. 1 Dimensions of the treatment gap continuum. It is hypothesized that lifetime access gap would be the smallest, while recovery gap would
be the largest. Equity (whether access to adequate, quality and effective treatment provision is affected by various personal and demographic
characteristics) is relevant to all the treatment gap types
Fekadu et al. BMC Psychiatry          (2019) 19:325 Page 4 of 11
exploring receipt of: (1) biomedical care; (2) Faith and
Traditional Healing (FTH); (3) Community care (assist-
ance from community residents and leaders, religious in-
stitutions, social organisations, NGOs); (4) support from
family and friends; (5) general self-care; (6) overall ex-
perience and impact or consequence of treatment gap
and dignity in care. Details within these main dimen-
sions explored four treatment gap themes or dimensions
(Fig. 1): Access to care (lifetime and current access); ad-
equacy of care (for the current access); quality of care
(for the current access); and effectiveness of care (per-
ceived benefit of care for the current access).
Adequacy of care was adapted from a study by Wang
and colleagues that used frequency of visits as an indica-
tor of adequacy [19]. Thus, based on evidence from pri-
mary and speciality care, Wang and colleagues
considered four or more visits of follow-up and medica-
tion monitoring for “acute and continuation phases of
treatment for mood, anxiety and psychotic disorders” as
minimally adequate. Quality of care was assessed
through satisfaction with provided care. Effectiveness
was measured from the participants’ perspective, in
terms of whether they felt they had benefited from or
harmed by the treatment they received. Under the FTH
section, 12 types of locally relevant “healing” providers
were included. The most widely used FTH across the
country is “Holy Water” treatment, in which water
which has been sanctified through prayer is sprinkled on
a patient for healing and protection. Finally, in a section
on “dignity in care”, the overall experience of care was
assessed with a focus on negative experiences, including
homelessness, accidents and assaults, restraint and im-
prisonment. The questions to estimate the treatment
gap assessed positive care receipt from which the treat-
ment gap was estimated.
The TGQ was developed as a pragmatic field tool by
the Ethiopia team through a series of consensus meet-
ings to agree on the key dimensions of the TG and how
to measure these dimensions. The study was part of an
initial pilot of the tool. We have not carried out formal
validation study. Nevertheless, the reliability of the scale
measured through the internal consistency coefficients,
Cronbach’s alpha, was generally satisfactory—highest
score was obtained for perceived benefit in care or re-
covery (α = 0.97). The coefficient for quality of care was
also good (α = 0.83).
Illness severity, and other measures
Clinical severity of symptoms was assessed with the Brief
Psychiatric Rating Scale- Expanded version (BPRS- E)
[30], a 24-item instrument, which has been used previ-
ously in Ethiopia [31]. The World Health Organization
Disability Assessment Schedule (WHODAS 2.0, [32]),
which measures the level of difficulty in daily activities
and social participation experienced in the previous 30
days [33] and has been adapted for use in Ethiopia [34,
35] was employed to measure functional impairment.
The quality of social support was assessed with the Oslo
3 Social Support Scale (OSS) [36].
Administration of assessment instruments
The main clinical assessment instruments (OPCRIT and
BPRS-E) were administered by trained psychiatric
nurses, while the TGQ and the other psychosocial scales
were administered by trained lay data collectors. These
data collectors were high school graduates with two to
four years of additional technical or professional train-
ing. They were trained for five days for the data collec-
tion and by the time they administered these
instruments they already had a one year experience of
administering various instruments for the PRIME study.
Data management
Data were double-entered into Epidata version 3.1 and
analysed using STATA version 13.1 (StataCorp, 1985–
2013). Simple descriptive analyses were used to summar-
ise socio-demographic factors along with service use and
treatment gap profiles.
An exploratory multivariable analysis was carried out
using logistic regression to assess for factors associated
with the use of biomedical services in the current access.
The selected factors were considered theoretically rele-
vant determinants of use of services, such as education,
income, social support and service use behaviour as indi-
cated by the use of FTH. Further exploratory analysis in-
cluded evaluation of the potential link between adequacy
of biomedical care and adverse experiences.
Results
Demographic and clinical characteristics
A total of 300 participants were included in the study.
Participants were predominantly of the Gurage ethnic
origin (n = 285; 94.7%), Orthodox Christian (n = 271;
90.0%) and rural residents (n = 240; 80%). Men were
slightly overrepresented (n = 173; 57.5%) (Table 2). Over
four fifths had a diagnosis of a schizophrenia spectrum
disorder (n = 244; 81.3%) (Table 2). A small minority
had affective psychosis (n = 40; 13.3%). Overall, partici-
pants had a moderate severity of illness and disability
measured with the BPRS-E (mean, SD = 47.3, 17.1) and
WHODAS (mean, SD = 51.5, 23.5).
The treatment gap
Lifetime access gap
The lifetime access to FTH was the highest (Table 3),
with 84.9% (n = 254) of participants having accessed
this modality of care. Over half of the participants
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(58.2% (n = 174) had accessed biomedical care
(specialist mental health services) at some point dur-
ing the illness. Thus, the lifetime access gap was 15
and 41.8% for FTH and biomedical care respectively.
Lifetime experience of admission (staying for at least
24 h in a facility for the purposes of treatment) for
FTH was 76.3% (n = 229) and for biomedical care
21.3% (n = 64).
Current access gap
Access to outpatient care for a biomedical psychiatric
service provider was 40.1% (n = 120) and for that of FTH
provider was 54.8% (n = 164) corresponding with a
current access gap of 59.9% for biomedical care and
45.2% for FTH. A much lower proportion of people re-
ported admission for their current episode either to psy-
chiatric hospitals (n = 22; 7.3%) and/or FTH providers
(n = 118; 38.0%).
Adequacy, quality and equity gaps
Regarding adequacy of biomedical care received in
the current episode (Table 4), 31.2% of those who
accessed care (n = 34/109) reported minimally ad-
equate care. This equates to only 11.3% of the total
sample of participants (n = 34/300). The overall satis-
faction in care, measuring the presumed construct of
Table 2 Background characteristics of participants (n = 300 unless specified)
Characteristics Number Percent
Gender Male 172 57.3
Female 128 42.7
Age 18–24 65 21.7
25–34 82 27.3
35–44 79 26.3
45–54 46 15.3
55 and above 28 9.3
Residence Urban 60 20.1
Rural 239 79.9
Education Illiterate 118 39.3
No formal education but can read and write 39 13.0
Formal education 143 47.7
Employment (n = 299) Agricultural work 76 25.4
self employed 16 5.4
House wife 58 19.4
Other employment 39 13.0
Unemployed 110 36.8
Income low and below 191 .63.7
Medium and above 109 36.3
Marital status Single 136 45.3
Married 111 37.0
Divorced 40 13.3
Widowed 13 4.3
Religion Orthodox Christian 271 90.0
Other 30 10.0
Ethnicity (n = 299) Gurage 281 94.0
Other 18 6.0
Children (n = 295) Yes 157 53.2
No 138 46.8
Children under 18 (n = 157) Yes 126 80.3
Summary diagnosis Schizophrenia spectrum disorders 256 85.3
Affective psychosis 44 14.7
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quality of care, was generally good, with 68.5% of
those using biomedical care reporting satisfaction with
the service.
The perceived benefit and satisfaction measuring quality
of care from biomedical care and a specific type of FTH
(holy water) was comparable. However, other FTHs, in
addition to having been used less, were considered of
lower quality and associated with reports of higher harm.
Those with formal education (Adj. OR; 95% CI = 2.1; 1.2,
3.8) and those who had used FTH (Adj. OR; 95% CI = 3.2;
1.9, 5.4) were more likely to use biomedical care (Table 5).
Potential consequences of the treatment gap
Several adverse outcomes and experiences were recorded
(Fig. 3) although not all may be accounted for by the
treatment gap. The most common were experiences of
Table 3 Prevalence of care receipt by type of provider
Care Type Number Percent
Inpatient care-Lifetime (n = 300) Biomedical 64 21.3
FTH 229 76.3
Inpatient care-Most recent episode (n = 300) Biomedical 22 7.3
FTH 114 38.0
Outpatient care-Lifetime (n = 299) Biomedical 174 58.2
FTH 254 84.9
Outpatient care- Most recent episode (n = 299) Biomedical 120 40.1
FTH 164 45.2
Informal sector (lifetime)
Family 286 95.7
Neighbours 69 23.0
Religious organisations 31 10.3
Social groups (Idir) 10 3.3
NGOs 5 1.7
Friends (n = 292) 46 15.8
Self-support/self help 257 85.7
Community support 69 23.0
FTH Faith and Traditional Treatment, NGOs Non-Governmental Organizations
Table 4 Adequacy, quality and perceived benefit of care for treatment in recent episode
Service characteristic Service type
Biomedical FTH
N Percent N Percent
Adequacy of care
(Biomedical = 109)a
Inadequate treatment 75 68.8 – –
bMinimally Adequate 34 31.2 – –
Perceived benefit
(N=Biomedical = 112)
(N=Holy water = 149)
Complete improvement 37 33.0 49 32.9
Some improvement 63 56.3 76 51.0
No improvement 12 10.7 23 15.4
Harm 0 0.0 1 0.7
Satisfaction in care (measuring quality)
Biomedical (111)
(FTH = 150)
Very satisfied 34 25.5 21 14.0
Satisfied 46 43.0 52 34.7
Neutral 21 18.8 32 21.3
Dissatisfied 7 8.1 32 21.3
Very dissatisfied 3 4.7 13 8.7
aData not collected for Faith & Traditional providers as there is no guideline for this
FTH Faith and Traditional Treatment
bMinimally adequate treatment defined as receipt of appropriate treatment with at least four monitoring visits
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physical restraint, reported by 46.3% (n = 139) of partici-
pants. Experience of homelessness also affected more
than a third of the sample (36.3%, n = 109). Other trau-
matic experiences included physical assault, sexual as-
sault and accidents. Further exploration of the potential
relationship between such adverse outcomes and ad-
equacy of biomedical care suggested a link with not re-
ceiving minimally adequate biomedical treatment (See
Additional file 1). However, in regression analysis, there
was no significant association between the treatment gap
Table 5 Associations of selected patient characteristics and likelihood of receiving biomedical treatment in the last 12 months
Characteristics Response categories Number
interviewed
% who received
biomedical treatment
Crude Odds Ratio
(95% Confidence Interval)
Adjusted Odds Ratio
(95%Confidence Interval)
Sex Male 172 36.6 Ref
Female 128 44.5 1.39 (0.87,2.21) 1.55 (0.92, 2.61)
Residence Urban 60 41.7 Ref
Rural 239 39.8 0.92 (0.52,1.64) 1.11 (0.57,2.18)
Education Illiterate 157 32.5 Ref
Read and write 53 37.7 1.26 (0.66,2.41) 1.27 (0.62, 2.62)
Formal Education 89 53.9 2.43 (1.43,4.15) 2.40 (1.27,4.53)
Relative wealth Low or very low 191 38.7 Ref
Medium or above 109 42.2 1.15 (0.72,1.86) 0.96 (0.57,1.62)
Received traditional treatment
in the last 12 months
No 136 25.0 Ref
Yes 164 52.4 3.31 (2.02,5.42) 3.22 (1.90,5.49)
Mean (SD)
Age 300 35.5 (13.5) 0.99 (0.97,1.00) 1.00 (0.98,1.02)
BPRSE 294 48.5 (15.6) 1.00 (0.98,1.01) 1.00 (0.98,1.02)
Social support 300 9.4 (2.4) 1.09 (0.99,1.21) 1.06 (0.95, 1.19)
BPRSE Brief Psychiatric Rating Scale Expanded Version
Fig. 3 Potential consequences of the treatment gap
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and selected adverse outcomes (homelessness, restraint
and assault) (Figures not shown).
Access to other sources of care
The family was reported to be the main source of sup-
port for patients, with less than a quarter reporting any
input from neighbours (23.0%), friends (15.8%), the com-
munity (23.0%), social organisations (3.3%), religious in-
stitutions (10.3%) or NGOs (1.7%). On the other hand,
almost the same proportion who reported support also
reported harm from these resources.
Discussion
To our knowledge this is the first in-depth exploration
of the mental health treatment gap and its potential im-
pact in Africa or any other LMIC setting. Although not
observed nationally [9], the study indicates a twofold re-
duction in the lifetime access gap since the first report
of the treatment gap in the neighbouring district of
Butajira 15 years earlier (90% vs. 42%) [11, 37]. This dif-
ference might have been partly due to the Butajira re-
search project on severe mental disorders that has been
operating over the past 15 years and supporting access
to biomedical care [12]. Therefore, people in our study
site, which is only about 30 kms from Butajira, are more
likely to benefit from the service in Butajira. However,
key informants, particularly health extension workers,
are more likely to recognise those with more severe ill-
ness and those who may already be known to the com-
munity and on treatment. This can underestimate the
treatment gap. Nevertheless, even with the potentially
underestimated treatment gap figure, the lifetime treat-
ment gap remains too high and access to minimally ad-
equate care unacceptably low. This study also
demonstrates that equity may be an important issue as
education and access behaviour were associated with ac-
cess to biomedical care.
FTHs are the predominant source of care in the study
area and more broadly in Ethiopia and will remain im-
portant in the longer term. Holy water treatment had
good perceived benefit and satisfaction. However, there
is no objective evidence that FTHs help in improving se-
vere mental disorders [38] and the self-reported im-
provement in this study might in part be to do with the
religious consonance of the treatment modality, given
most patients were Orthodox Christians. Objective in-
vestigation of potential benefits and potential synergy
with biomedical care is required. Anecdotal experience
suggests some of the FTH providers, such as tenquay
(soothsayer), are less acceptable and their use is likely to
be higher than reported. Yet, given the higher rates of
reported harms among users of these treatments, further
investigation of their use and working with the public to
ensure protection of patients is important.
Although families have some role in the care of pa-
tients with mental illness globally, the family is the “crit-
ical unit” [39] of care in LMICs. Virtually all care in this
setting is provided by the family. Despite the availability
of a wide range of community resources, including
nearly 300 social organisations, over 400 religious
groups, NGOs and other resources in the study district
[40], access to such community resources was disap-
pointingly low leaving the burden of care almost entirely
on the family. Mobilising these resources through add-
itional interventions, for example applying the Basic
Needs model [41] or the Community Based Rehabilita-
tion Model that is being employed in an ongoing clinical
trial study in the area [42, 43], may be important.
The high level of traumatic experiences such as phys-
ical restraint, homelessness and actual physical abuse of
people with psychosis is of major concern. Although the
traumatic experiences may not entirely be a direct result
of the treatment gap, the large treatment gap is likely to
be contributory to these negative experiences. In rural
villages, people with psychosis induce fear and are per-
ceived as unpredictable and violent [44]. Such a percep-
tion, combined with lack of effective treatment, may lead
to restraint and even other physical abuse. Preliminary
work in the setting indicates that the lack of care alter-
natives may be the overriding reason for the physical re-
straint [15]. The lack of legal mechanisms, low
awareness among the public about mental disorders and
the place of people with mental illness in society exposes
people with mental illness to harm.
Scaling up mental healthcare is a crucial step for ad-
dressing the broader violation of the rights of people
with mental illness [45]. As shown, providing minimally
adequate care may reduce these violations and victimisa-
tions although the study design would not allow us to
confirm this conclusively.
Several limitations to this study are worth mentioning.
First, the study is cross-sectional, yet many of the ques-
tions ask for lifetime recall. This was unavoidable be-
cause part of the focus of the study was intentionally
lifetime experience as important index of the level of
neglect. Second, although the tool for measuring treat-
ment gap was developed carefully by mental health re-
searchers and practitioners, including social workers,
with understanding of the local context, the measure
would benefit from further adaptation and simplifying.
For example, the measure of the quality of care was
assessed through satisfaction in care. Satisfaction is only
one dimension of quality of care and evidently inad-
equate to evaluate quality of care; nevertheless, satisfac-
tion may serve as a simple proxy measure in large
population-based studies. Adequacy of care was also
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measured in a relatively crude way although the measure
has been applied previously. We also conducted an ana-
lysis of association between adequacy of care for treat-
ment received for the most recent episode and lifetime
untoward experiences or abuses. This was carried out as
an exploratory examination of the potential impact of
the treatment gap. On the other hand, we expected that
the pattern of neglect or abuse would be consistent over
the course of the illness. If a patient is restrained in one
episode, we anticipated that that patient is more likely to
be restrained in subsequent episodes unless adequate
treatment was provided. The effectiveness and recovery
gaps were also not measured because doing so would re-
quire prospectively following up participants.
Conclusion
Viewing the treatment gap in psychosis as a multi-
dimensional construct offers a more realistic and holistic
understanding of the need for care and may assist policy
and advocacy efforts. The community and NGOs can
play a bigger role in supporting mental healthcare in
rural Ethiopia. Our findings indicate the need to further
increase service availability and the need to ensure ad-
equacy of treatment. The use of other FTH is probably
higher than reported; this study calls for further robust
data on the benefits and harms of FTH and potential
synergy with biomedical care. Cultural competence in
protecting the dignity of people with mental illness
should be a priority for providers and governments.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12888-019-2281-6.
Additional file 1. Exploratory analysis of “adequacy” of treatment
measured through frequency of visit to biomedical provider and
relationship with measures of adverse illness outcomes.
Abbreviations
BPRS- E: Brief Psychiatric Rating Scale Expanded version; FTH: Faith and
Traditional Healing; ICD: International Classification of Diseases; LMIC: Low
and Middle-Income Countries; NGOs: Non-Governmental Organisations;
OPCRIT: Operational Criteria for Research; OSS: Oslo 3 Social Support Scale;
PRIME: Programme for Improving Mental Healthcare; SCAN: Schedules for
Clinical Assessment in Neuropsychiatry; SNNPR: Southern Nations,
Nationalities and Peoples’ Region; TGQ: Treatment Gap Questionnaire;
WHODAS: World Health Organization Disability Assessment Schedule
Acknowledgements
The authors would like to acknowledge the substantial support and
partnership of the Sodo district administration and health office.
Authors’ contributions
All authors (AF, GM, CL, MD, MS, AA, LA, RB, VP, MH, TS, GT, MP and CH)
contributed to the design of the study, data interpretation and writing of the
manuscript and all authors have read and approved the final manuscript. AF,
GM, MS, CH, RB contributed to data collection. GM and AF conducted data
analysis. AF conducted the literature search and wrote the initial draft. AF,
GM and CH developed the TGQ)
Funding
This study was part of the PRIME Project, which was supported by the UK
Department for International Development [201446]. The views expressed do
not necessarily reflect the UK Government’s official policies. The funder had
no role in the plan or the publication of this paper.
AF is supported by the MRC/DFID under the African Research Leader
scheme (Grant Ref: MR/M025470/1). The funder had no role in the plan or
the publication of this paper.
GT is supported by the National Institute for Health Research (NIHR)
Collaboration for Leadership in Applied Health Research and Care South
London at King’s College London NHS Foundation Trust. The views
expressed are those of the author(s) and not necessarily those of the NHS,
the NIHR or the Department of Health. GT acknowledges financial support
from the Department of Health via the National Institute for Health Research
(NIHR) Biomedical Research Centre and Dementia Unit awarded to South
London and Maudsley NHS Foundation Trust in partnership with King’s
College London and King’s College Hospital NHS Foundation Trust. GT is
supported by the European Union Seventh Framework Programme (FP7/
2007–2013) Emerald project.
Availability of data and materials
The data are part of the PRIME project and will be made available at the end
of the project. But the data may be requested from the corresponding
author for verification of the analyses in this paper.
Ethics approval and consent to participate
Ethical approval was obtained from the College of Health Sciences
Institutional Review Board, Addis Ababa University (Ref. 026/15/Psy) and the
University of Cape Town ethics review board (HREC REF: 412/2011). Written
informed consent was obtained from literate participants. For non-literate
respondents, verbal consent was accompanied by a finger print in the pres-
ence of a literate witness. The consent procedure was also approved by the
ethics review board. All participants with severe mental illness (SMD) were
offered mental health care through the PRIME project. For people with SMD
who lacked capacity to consent and were not refusing participation, care-
giver permission was obtained.
Competing interests
The Authors declare that they have no competing interest.
Author details
1Center for Innovative Drug Development and Therapeutic Trials for Africa
(CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia. 2Global Health &
Infection Department, Brighton and Sussex Medical School, Brighton, UK.
3College of Health Sciences, School of Medicine, Department of Psychiatry,
Addis Ababa University, Addis Ababa, Ethiopia. 4Aklilu Lemma Institute of
Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia. 5Alan J Flisher
Centre for Public Mental Health, Department of Psychiatry and Mental
Health, Addis Ababa University, University of Cape Town, Cape Town, South
Africa. 6Centre for Global Mental Health, Health Service and Population
Research Department, King’s College London, Institute of Psychiatry,
Psychology and Neuroscience, London, UK. 7The Wellcome Trust, London,
UK. 8Division of Epidemiology and Public Health, School of Medicine,
University of Nottingham, Nottingham, UK. 9Department of Global Health &
Social Medicine, Harvard Medical School, Boston, USA. 10Department of
Psychiatry, Dalhousie University, Horizon Zone 3, Fredericton, NB, Canada.
Received: 22 October 2018 Accepted: 10 September 2019
References
1. Mbewu AD. Changing history--closing the gap in AIDS treatment and
prevention. Bull World Health Organ. 2004;82:400.
2. Supina AL, Guirguis LM, Majumdar SR, Lewanczuk RZ, Lee TK, Toth EL,
Johnson JA. Treatment gaps for hypertension management in rural
Canadian patients with type 2 diabetes mellitus. Clin Ther. 2004;26:598–606.
3. Braga M, Casanova A, Teoh H, Dawson KC, Gerstein HC, Fitchett DH, Harris
SB, Honos G, McFarlane PA, Steele A, et al. Treatment gaps in the
management of cardiovascular risk factors in patients with type 2 diabetes
in Canada. Can J Cardiol. 2010;26:297–302.
4. Kale R. The treatment gap. Epilepsia. 2002;43:31–3.
Fekadu et al. BMC Psychiatry          (2019) 19:325 Page 10 of 11
5. Patel V, Maj M, Flisher AJ, De Silva MJ, Koschorke M, Prince M, Zonal WPA.
Member society R. reducing the treatment gap for mental disorders: a WPA
survey. World Psychiatry. 2010;9:169–76.
6. Kohn R, Saxena S, Itzhak L, Saraceno B. The treatment gap in mental health
care. Bull World Health Organ. 2004;82:858–66.
7. Institute of Medicine Forum on N, Nervous System D, Uganda National
Academy of Sciences Forum on H, Nutrition. The National Academies
Collection. Reports funded by National Institutes of Health. In: Mental,
neurological, and substance use disorders in sub-Saharan Africa: reducing
the treatment gap, improving quality of care: summary of a joint workshop.
Edn. Washington, DC: National Academies Press (US) National Academy of
Sciences; 2010.
8. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP,
Angermeyer MC, Bernert S, de Girolamo G, Morosini P, et al. Prevalence,
severity, and unmet need for treatment of mental disorders in the World
Health Organization world mental health surveys. JAMA. 2004;291:2581–90.
9. Lora A. Service availability and utilization and treatment gap for
schizophrenic disorders: a survey in 50 low-and middle income countries.
Eur Arch Psychiatry Clin Neurosci. 2013;1:Suppl:52.
10. Lora A, Kohn R, Levav I, McBain R, Morris J, Saxena S. Service availability and
utilization and treatment gap for schizophrenic disorders: a survey in 50
low- and middle-income countries. Bull World Health Organ. 2012;90:47–
54–54a-54b.
11. Fekadu A, Kebede D, Alem A, Fekadu D, Mogga S, Negash A, Medhin G,
Beyero T, Shibre T. Clinical outcome in bipolar disorder in a community-
based follow-up study in Butajira, Ethiopia. Acta Psychiatr Scand. 2006;114:
426–44.
12. Kebede D, Alem A, Shibre T, Negash A, Fekadu A, Fekadu D, Deyassa N,
Jacobsson L, Kullgren G. Onset and clinical course of schizophrenia in
Butajira-Ethiopia--a community-based study. Soc Psychiatry Psychiatr
Epidemiol. 2003;38:625–31.
13. World Health Organization. Mental health action plan 2013–2020. Geneva:
WHO Press; 2013.
14. White RG, Orr DMR, Read UM, Jain S. Situating global mental health:
sociocultural perspectives. In: White RG, Jain S, Orr DMR, Read UM, editors.
The Palgrave handbook of socicultural perspectives on global mental
health. Edn. London: Macmillan Publishers; 2017. p. 1–27.
15. Asher L, Fekadu A, Teferra S, De Silva M, Pathare S, Hanlon C. "I cry every day
and night, I have my son tied in chains": physical restraint of people with
schizophrenia in community settings in Ethiopia. Glob Health. 2017;13:47.
16. World Health Organization. Organization of services for mental health
(mental health policy and service guidance package). Geneva WHO. 2003.
http://www.who.int/mental_health/policy/services/4_organisation%2
0services_WEB_07.pdf?ua=1. Accessed 17 March 2018.
17. Substance Abuse and Mental Health Services Administration. Leading
change 2.0: advancing the behavioral health of the nation 2015–2018.
Rockville, MD Substance Abuse and Mental Health Services Administration
(HHS publication no. (PEP) 14-LEADCHANGE2). 2014. http://store.samhsa.
gov/shin/content/PEP14-LEADCHANGE2/PEP14-LEADCHANGE2.pdf. .
18. U. S. Department of Health and Human Services Health Resources and
Services Administration. Quality Improvement.2011. https://www.hrsa.gov/
quality/toolbox/508pdfs/qualityimprovement.pdf. .
19. Wang PS, Demler O, Kessler RC. Adequacy of treatment for serious mental
illness in the United States. Am J Public Health. 2002;92:92–8.
20. Keller MB. Past, present, and future directions for defining optimal treatment
outcome in depression: remission and beyond. JAMA. 2003;289:3152–60.
21. Elkis H. Treatment-Resistant Schizophrenia. Psychiatr Clin North Am. 2007;30:511–33.
22. Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A,
Cleare AJ. What happens to patients with treatment-resistant depression? A
systematic review of medium to long term outcome studies. J Affect
Disord. 2009;116:4–11.
23. Lund C, Tomlinson M, De Silva M, Fekadu A, Shidhaye R, Jordans M,
Petersen I, Bhana A, Kigozi F, Prince M, et al. PRIME: a programme to reduce
the treatment gap for mental disorders in five low and middle-income
countries. PLoS Med. 2012;9. https://doi.org/10.1371/journal.pmed.1001359.
24. Fekadu A, Hanlon C, Medhin G, Alem A, Selamu M, Giorgis TW, Shibre T, Teferra
S, Tegegn T, Breuer E et al. Development of a scalable mental healthcare plan for
a rural district in Ethiopia. Br J Psychiatry 2016; 208:suppl 4–12.
25. Fekadu A, Medhin G, Selamu M, Hailemariam M, Alem A, Giorgis TW, Breuer
E, Lund C, Prince M, Hanlon C. Population level mental distress in rural
Ethiopia. BMC Psychiatry. 2014;14:194.
26. Shibre T, Kebede D, Alem A, Negash A, Kibreab S, Fekadu A, Fekadu D,
Jacobsson L, Kullgren G. An evaluation of two screening methods to
identify cases with schizophrenia and affective disorders in a community
survey in rural Ethiopia. Int J Soc Psychiatry. 2002;48:200–8.
27. World Health Organization. The international classification of diseases. 10th
ed. Geneva: World Health Organization; 1992.
28. McGuffin P, Farmer AE, Harvey I. A Polydiagnostic application of operational
criteria in studies of psychotic illness: development and reliability of the
OPCRIT system. Arch Gen Psychiatry. 1991;48:764–70.
29. World Health Organization. Schedules for clinical assessment in
neuropsychiatry, version 2.1 edn. Geneva: World Health Organization; 1997.
30. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical
implications of brief psychiatric rating scale scores. Br J Psychiatry. 2005;187:
366–71.
31. Youngmann R, Zilber N, Workneh F, Giel R. Adapting the SRQ for Ethiopian
populations: a culturally-sensitive psychiatric screening instrument. Transcult
psychiatry. 2008;45:566–89.
32. Ustun TB, Kostanjesek N, Chatterji S, Rehm J, Organization. WH. Measuring
health and disability: manual for WHO disability assessment schedule
(WHODAS 2.0): Geneva World Health Organization; 2010. http://www.who.
int/iris/handle/10665/43974. Accessed 20 April 2016
33. Chang K-H, Lin Y-N, Liao H-F, Yen C-F, Escorpizo R, Yen T-H, Liou T-H.
Environmental effects on WHODAS 2.0 among patients with stroke with a
focus on ICF category e120. Qual Life Res. 2014;23:1823–31.
34. Habtamu K, Alem A, Medhin G, Fekadu A, Prince M, Hanlon C. Development
and validation of a contextual measure of functioning for people living with
severe mental disorders in rural Africa. BMC Psychiatry. 2016;16(311).
35. Habtamu K, Alem A, Medhin G, Fekadu A, Dewey M, Prince M, Hanlon C.
Validation of the World Health Organization disability assessment schedule
in people with severe mental disorders in rural Ethiopia. Health Qual Life
Outcomes. 2017;15:64.
36. Dalgard OS, Dowrick C, Lehtinen V, Vazquez-Barquero JL, Casey P, Wilkinson
G, Ayuso-Mateos JL, Page H, Dunn G. Negative life events, social support
and gender difference in depression: a multinational community survey
with data from the ODIN study. Soc Psychiatry Psychiatr Epidemiol. 2006;41:
444–51.
37. Alem A, Kebede D, Fekadu A, Shibre T, Fekadu D, Beyero T, Medhin G,
Negash A, Kullgren G. Clinical course and outcome of schizophrenia in a
predominantly treatment-naive cohort in rural Ethiopia. Schizophr Bull.
2009;35:646–54.
38. Nortje G, Oladeji B, Gureje O, Seedat S. Effectiveness of traditional healers in
treating mental disorders: a systematic review. Lancet Psychiatry. 2016;3:
154–70.
39. Susser E, Collins P. Topics for our times: can we learn from the Care of
Persons with mental illness in developing countries? Am J Public Health.
1996;86:926–7.
40. Selamu M, Asher L, Hanlon C, Medhin G, Hailemariam M, Patel V, Thornicroft
G, Fekadu A. Beyond the biomedical: community resources for mental
health Care in Rural Ethiopia. PLoS One. 2015;10. https://doi.org/10.1371/
journal.pone.0126666.
41. BasicNeeds.Our Approach.http://www.basicneeds.org/our-approach/.
Accessed 06 September 2017.
42. Asher L, De Silva M, Hanlon C, Weiss HA, Birhane R, Ejigu DA, Medhin G,
Patel V, Fekadu A. Community-based rehabilitation intervention for people
with schizophrenia in Ethiopia (RISE): study protocol for a cluster
randomised controlled trial. Trials. 2016;17:299.
43. Asher L, Fekadu A, Hanlon C, Mideksa G, Eaton J, Patel V. Development of a
community-based rehabilitation intervention for people with schizophrenia
in Ethiopia. PLoS One. 2015;10. https://doi.org/10.1371/journal.pone.
0143572.
44. Shibre T, Teferra S, Morgan C, Alem A. Exploring the apparent absence of
psychosis amongst the Borana pastoralist community of southern Ethiopia.
A mixed method follow-up study. World Psychiatry. 2010;9:98–102.
45. Hanlon C, Eshetu T, Alemayehu D, Fekadu A, Semrau M, Thornicroft G,
Kigozi F, Marais DL, Petersen I, Alem A. Health system governance to
support scale up of mental health care in Ethiopia: a qualitative study. Int J
Ment Health Syst. 2017;11:38.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Fekadu et al. BMC Psychiatry          (2019) 19:325 Page 11 of 11
